| Literature DB >> 23834773 |
Zhao-Yan Jiang1, Chen-Ying Xu, Xian-Xing Chang, Wei-Wei Li, Lu-Ying Sun, Xiao-Bo Yang, Li-Fen Yu.
Abstract
BACKGROUND: Fatty liver index (FLI) was recently established to predict non-alcoholic fatty liver disease (NAFLD) in general population, which is known to be associated with coronary artery atherosclerotic disease (CAD).This study aims to investigate whether FLI correlates with NAFLD and with newly diagnosed CAD in a special Chinese population who underwent coronary angiography.Entities:
Mesh:
Substances:
Year: 2013 PMID: 23834773 PMCID: PMC3710104 DOI: 10.1186/1471-230X-13-110
Source DB: PubMed Journal: BMC Gastroenterol ISSN: 1471-230X Impact factor: 3.067
Figure 1Fatty liver index (FLI) was significantly higher in patients with NAFLD than in patients without NAFLD (non-NAFLD), 37.10 ± 1.95 17.70 ± 1.04, < 0.01.
Distribution of NAFLD and non-NAFLD subjects in different FLI categories
| NAFLD | 100 (25.8%) | 56 (48.3%) | 53 (74.6%) | <0.01 |
| Non-NAFLD | 287 (74.2%) | 60 (51.7%) | 18 (25.4%) | <0.01 |
*Cochran-Armitage test for trend between three FLI categories.
Figure 2AUC-ROC of FLI for prediction of fatty liver (value = 0.721, 95% CI: 0.678-0.764). FLI, fatty liver index; AUC, area under curve; ROC: receiver operating curve.
Multivariate logistic regression analysis of factors associated with NAFLD
| FLI | 1.038 (1.029-1.047) | < 0.01 |
| History of hypertension | 1.627 (1.051-2.519) | 0.029 |
| History of diabetic mellitus | 1.890 (1.190-3.003) | 0.007 |
| History of dyslipidemia | 1.414 (1.006-2.217) | 0.047 |
Distribution of patients with and without CAD in different FLI categories
| CAD (n = 231) | 156 (32.3%) | 45 (31.0%) | 30 (35.3%) | >0.05 |
| Non-CAD (n = 482) | 327 (67.7%) | 100 (69.0%) | 55 (64.7%) | >0.05 |
*Cochran-Armitage test for trend between three FLI categories.
Multivariate logistic regression analysis of factors associated with CAD
| | ||||
|---|---|---|---|---|
| Age | 1.049 (1.021–1.077)** | 1.047 (1.019–1.075)** | 1.061 (1.019–1.106)** | 1.055 (1.012–1.100)* |
| Smoking | 1.404 (0.760–2.593) | 1.390 (0.748–2.582) | 0.759 (0.122–4.729) | 0.750 (0.120–4.689) |
| Alcohol intake | 0.441 (0.243–0.801)** | 0.451 (0.246–0.828)** | 3.384 (0.416–27.532) | 2.858 (0.357–22.863) |
| History of hypertension | 1.289 (0.714–2.328)* | 1.079 (0.579–2.011) | 2.774 (0.989–7.779) | 1.850 (0.638–5.359) |
| History of dyslipidemia | 2.034 (1.169–3.538)* | 1.996 (1.142–3.489)* | 1.494 (0.718–3.105) | 1.656 (0.781–3.512) |
| History of DM | 0.379 (0.163–0.883) | 0.419 (0.146–1.206) | 0.612 (0.237–1.581) | 0.925 (0.231–3.710) |
| ALP | 1.000 (0.986–1.015) | 0.999 (0.984–1.014) | 0.997 (0.981–1.014) | 0.996 (0.979–1.013) |
| TC | 1.745 (1.393–2.185)** | 1.752 (1.395–2.200)** | 1.292 (1.007–1.658)* | 1.293 (1.005–1.664)* |
| HDL | 0.275 (0.097–0.785)* | 0.305 (0.104–0.894)* | 0.191 (0.051–0.710)* | 0.196 (0.052–0.742)* |
| FPG | 1.282 (1.052–1.563)* | 1.264 (1.036–1.543)* | 1.224 (0.981–1.526) | 1.348 (1.050–1.731)* |
| FLI | 0.990 (0.980–1.001) | 0.991 (0.980–1.002) | 0.988 (0.965–1.012) | 0.985 (0.961–1.010) |
a: adjusted for anti-hyerlipidimia and diabetic mellitus drug therapy.
* represents P < 0.05 and ** represents P < 0.01.